FNP-223, previously known as ASN90, is a reversible and substrate-competitive O-GlcNAcase enzyme inhibitor. The oral investigational drug is expected to rapidly increase O-GlcNAcylated tau proteins, ...

“When she would fall in public, people just assumed she was drunk,” said Glenn. “One time she fell backwards on the steps and ...

So, let’s talk about faith. I’m no rabbi or scholar, and I’m not trying to write a religious work. But putting my thoughts ...

In The Salt Path, Raynor Winn writes that she and her husband lost their home after investing a “substantial sum” into a ...

Researchers from Asan Medical Center, one of South Korea's largest hospitals, have developed a generative AI model that can ...

Commercial real estate player and former Kislak President Jeffrey Wiener died July 9 after a long battle with progressive ...

When progressive supranuclear palsy (PSP), a rare neurodegenerative disorder, started affecting his movement, his wife and ...

Progressive supranuclear palsy (PSP) affects persons in their late 60s to 70s, because of the shrinkage of the upper ...

TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.

A national charity claims people with severe neurological conditions being unfairly denied access to free care.

Kinetic measures of a cerebrospinal fluid (CSF) biomarker test predicted cognitive decline in Parkinson's disease and distinguished it from progressive supranuclear palsy (PSP), an analysis of ...

Raynor Winn's 2018 memoir The Salt Path is billed as a "true story" based on her and her husband Moth's 630-mile trek along ...